Scarica l'app Stockscreener
101.88
2.03%
-2.11
Pre-mercato:
102.75
0.87
+0.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$103.99
Aprire:
$104.76
Volume 24 ore:
10.06M
Relative Volume:
0.94
Capitalizzazione di mercato:
$177.03B
Reddito:
$44.33B
Utile/perdita netta:
$6.50B
Rapporto P/E:
27.41
EPS:
3.717
Flusso di cassa netto:
$7.40B
1 W Prestazione:
-2.83%
1M Prestazione:
-12.44%
6M Prestazione:
-23.46%
1 anno Prestazione:
-22.12%
Intervallo 1D:
$101.82
$104.77
Intervallo di 1 settimana:
$101.82
$105.98
Portata 52W:
$101.82
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
101.88 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
326.10 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.74 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.93 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
79.50 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
BTIG Research Adjusts Abbott Laboratories PT to $131 From $140, Maintains Buy Rating - marketscreener.com
Whoop Raises $575M at $10.1B Valuation, Abbott Joins as Investor - athletechnews.com
Abbott Laboratories $ABT Position Trimmed by J. Safra Sarasin Holding AG - MarketBeat
Abbott Laboratories $ABT Shares Bought by Mn Services Vermogensbeheer B.V. - MarketBeat
Abbott (ABT) Enhances Cancer Care with OncoEMR Test Integration - GuruFocus
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance Australia
Dairy industry consolidation | Lactalis, Abbott Complete Major NZ Dairy Deals - en.edairynews.com
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High - TechStock²
Abbott, Flatiron Health Integrate Precision Oncology Tests Into Oncology EMR Platform - Clinical Lab Products
Abbott Laboratories stock hits 52-week low at 102.39 USD - Investing.com
Abbott Laboratories stock hits 52-week low at 102.39 USD By Investing.com - Investing.com Australia
Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR - TipRanks
Abbott integrates cancer tests into Flatiron’s EMR platform By Investing.com - Investing.com India
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform - marketscreener.com
4,700 cancer providers can now order Abbott tests in their records system - Stock Titan
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks - The Motley Fool
Inside the high-stakes business battle over feeding preterm babies - USA Today
Is Abbott Laboratories (ABT) Offering Value After Recent Share Price Weakness? - simplywall.st
Chesley Taft & Associates LLC Has $30.29 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Net Worth Advisory Group Acquires Shares of 10,905 Abbott Laboratories $ABT - MarketBeat
Abbott subsidiary dodges whistleblower claim from fired remote worker - hcamag.com
Abbott Culture Alignment Supports Long Term Execution And Valuation Story - simplywall.st
Abbott Laboratories (ABT) announces completion of acquisition of Exact Sciences - MSN
Abbott Laboratories Faces Weak Start with Gap Down Amid Market Concerns - marketsmojo.com
Abbott Labs Eludes Kentucky State-Law Claims in Heart Valve Suit - Bloomberg Law News
Clinical Nutrition for Diabetes Care Market Report 2026-2030 Featuring Profiles of Key PlayersPfizer, Bayer, Sanofi-Aventis, Abbott Labs, Roche and More - globenewswire.com
Abbott Laboratories Revenue Breakdown – BSESOF:ABL - TradingView
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Merck & Company (MRK) and Abbott Laboratories (ABT) - The Globe and Mail
Abbott Laboratories $ABT Shares Acquired by Dakota Wealth Management - MarketBeat
Abbott Unit Beats Ex-Worker's Whistleblower Suit At 8th Circ. - Law360
Vanguard disaggregates holdings; ABT shows 0 shares (ABT) - Stock Titan
Abbott Labs Worker’s Wrongful Termination Suit Fails on Appeal - Bloomberg Law News
What Abbott Laboratories (ABT)'s Cancer Screening Deal and Libre Data Reveal About Its Chronic Care Ambitions - simplywall.st
Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences - Yahoo Finance
NEC Baby Formula Lawsuit & Settlement | March 2026 Update - lawsuit-information-center.com
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
Abbott hosts conference call for first-quarter earnings - Abbott MediaRoom
Abbott will report first-quarter results before markets open April 16 - Stock Titan
Abbott Laboratories stock faces pipeline scrutiny amid diagnostics slowdown in Q1 2026 - AD HOC NEWS
Abbott (NYSE: ABT) SVP receives 13,255-share restricted stock award - Stock Titan
[Form 3] ABBOTT LABORATORIES Initial Statement of Beneficial Ownership - Stock Titan
Mom Tying Abbott Formula To Baby's NEC Takes The Stand - Law360
Why Abbott (ABT) Is Betting $23B on Cancer Screening - MarketWise
Abbott Earnings Preview: What to Expect - Barchart.com
Pensionfund Sabic Takes Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Hits Day Low of $105.40 Amid Price Pressure - Markets Mojo
Abbott Laboratories Hits New 52-Week Low at USD 104.11 - Markets Mojo
Abbott Laboratories stock faces pressure amid diagnostics slowdown and FreeStyle Libre competition i - AD HOC NEWS
List of 29 Acquisitions by Abbott (Mar 2026) - Tracxn
Is It Time To Reconsider Abbott Laboratories (ABT) After Recent Share Price Weakness? - Yahoo Finance
Abbott Proclaim SCS Lawsuit Alleges Stimulator Lead Migration Resulted in Multiple Surgeries - AboutLawsuits.com
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):